ASH 2019 | NGS for KD mutational analysis in CML patients on TKIs
Hugues de Lavallade
• 7 Dec 2019
Kinase domain mutations in the BCR-ABL1 gene are associated with resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML). Hugues de Lavallade, MD, PhD, King’s College London, London, UK, discusses the interim analysis of a prospective non-interventional study (NCT03647215) of centralized next-generation sequencing (NGS) screening to detect kinase domain mutations, in order to evaluate the use of NGS in clinical practice. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
